World's Largest Pharmaceutical Chromatography Plant To Be Built in Europe
Novasep (Pompey, France) has announced an investment of €30 million into the construction of the world’s largest pharmaceutical chromatography plant.
Novasep (Pompey, France) has announced an investment of €30 million into the construction of the world’s largest pharmaceutical chromatography plant. The plant will be located on Novasep’s existing Mourenx site in France and will be used for the production of a large volume commercial API (active pharmaceutical ingredient).
The plant will be designed and planned by the company’s in-house engineers, with plans for the plant to be operational and validated within 18 months. The investment follows the projection of a rapid increase in demand for large volume, highly purified API from complex mixtures. The systems within the plant will reportedly incorporate solvent recovery systems for the recovery of 99.9% of solvents reducing environmental impacts of the plant.
"Demand for Novasep's advanced, purification-based manufacturing capabilities in the life science industries continues to increase as drugs in development and reaching the market become more complex and specific. This necessitates our third and largest global plant expansion in 2012," commented Patrick Glaser, President and CEO of Novasep." This project demonstrates the validity of the Novasep strategy which is based on the combination of synthesis, biosynthesis and purification. We thank our institutional partners for their active support and our shareholders for their strong involvement to enable this transforming project."
For more information please visit:
ref=http://www.novasep.com >www.novasep.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
